---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-035908"
form_type: "8-K"
ticker: "VIR"
cik: "0001706431"
company_name: "Vir Biotechnology, Inc."
filed_at: "2023-02-13T23:59:59+00:00"
generated_at: "2026-06-19T16:16:29.632845+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Vir Bio amends GSK deal: regains full rights to vaccine program, narrows antibody program

## Summary
- Amendments remove CoV Vaccine Program from collaboration; Vir retains rights to progress independently.
- CoV Antibody Program narrowed to only sotrovimab and VIR-7832; all other antibodies revert to Vir.
- Vir pays tiered royalties in low single digits on vaccine sales, low-to-mid single digits on terminated antibodies.
- Amendments effective March 31, 2022 (vaccine wind-down) and February 8, 2023 (antibody scope reduction).
- GSK retains 50:50 profit share on sotrovimab and VIR-7832 under original DCA terms.

## SEC filing metadata
- accession: 0001193125-23-035908
- form_type: 8-K
- ticker: VIR
- cik: 0001706431
- company_name: Vir Biotechnology, Inc.
- filed_at: 2023-02-13T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 1.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1706431/000119312523035908/0001193125-23-035908-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1706431/000119312523035908/d449379d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-035908
- JSON: https://secwatch.observer/filing/0001193125-23-035908.json
- Plain text: https://secwatch.observer/filing/0001193125-23-035908.txt

## Key facts
- Material Agreements
  Vir Biotechnology, Inc. entered into Amendment No. 2 and Amendment No. 3 to the DCA with GSK (effective 2023-02-08).
  - Action: entry
  - Agreement: collaboration
  - Counterparty: GSK
  - Effective: 2023-02-08
  source text: On February 8, 2023, the Company, and GSK entered into Amendment No. 2 and Amendment No. 3 to the DCA (collectively, the “DCA Amendments”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1706431/000119312523035908/0001193125-23-035908-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.